Tuesday, June 06, 2023 10:59:38 AM
I provided it. It is still into a second wave with an impressive amount of infection.
You have no response to that, when you yourself have at least twice that you expect new variants.
I point out several of your contradictions in your own writings, where you actually lay out your thoughts but you don't or cant explain the error, contradiction or weakness in your argument.
Instead, you change the subject with pure whataboutism.
You write that a phase 3 can't happen cause "seropositivity" as though one word is an answer, yet you warn us that the Pfizer next gen is coming as though - somehow - that molecule won't be subject to the same issues that Enanta's covid candidate faces.
You seem to suggest that it's viral decline that is the bar for approval when all evidence is that it is NOT the metric. You seem able to hold that thought when the Pfizer next gen candidate has not yet provided any such data in their phase 1 trial (have they even dosed participants yet?).
You seem to allege that where it is difficult to contrast viral load declines in dosed versus healthies as undercutting the efficacy of the drug but I suspect that you are aware that if it were in a more impaired group than healthies, or with a nastier variant like Delta or a lesser seropositive cohort the results would be more differentiated.
Rather than answering any of these contradictions you pivot.
If no partnership has been announced you must be right.
We will see what happens- nobody knows until it happens or it doesn't happen.
These things take time- as I suspect that you know.
Is there/has there been a market for Remdesivir? Was that approval based on viral decline?
The same for Paxlovid?
You see, I had thought that approval was based on outcomes.
Are further Phase 3 trials for covid possible? Pfizer and others seem to think so.
Should I believe Pfizer or you?
Your usual pattern is to scare, cast aspersions, create doubt.
Who do you like? Where have you plunked down your money? I don't recall having read that.
Yet many of us have been straightforward in that area with you but you only seem to be able to dish it.
Are you that insecure in your beliefs?
Dew posted to you in Biotech values but you answer with word salad.
"No deal, high seropositivity, Pfizer 2nd gen… going to be a rough road there."
---For a brilliant guy you don't express yourself very well. It's not even a sentence and where you were called for an explanation, here too you pivoted, avoided "The second post I was actually posing the question to you" or answered with more word salad without any clarification; "For the first point, I never commented on viral load reduction but actually antiviral effects".
--that's an explanation?
A guy with more confidence would explain clearly their position and be prepared to defend their thesis.
I don't see that happening in your posts.
It's just mostly about throwing stones.
I probably have the least amount of technical background in biotech compared to many others here.
I'm straight from the trenches; a guy who was infected and cured through his involvement in biotech- cured in a Gilead HVC registration trial.
I suspect that you have a deeper understanding of some of the technical aspects than I do.
So, here's my question.
Why don't you just share your views, explain them clearly and attempt to validate them?
I would find that helpful.
Recent ENTA News
- Enanta Pharmaceuticals to Participate in Investor Conferences in September • Business Wire • 09/03/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 09:24:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:10 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Business Wire • 08/05/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 09:29:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 12:38:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:15:05 PM
- Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:37:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:00:34 PM
- Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference • Business Wire • 05/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:14 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 05/06/2024 08:01:00 PM
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 11:10:00 AM
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer • Business Wire • 04/30/2024 11:00:00 AM
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 • Business Wire • 04/29/2024 11:00:00 AM
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
FEATURED Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM